# A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

> **NCT06169319** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 231 (actual)

## Conditions studied

- Plantar Fasciitis

## Interventions

- **BIOLOGICAL:** Collagenase Clostridium Histolyticum (CCH)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06169319
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-03
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169319, "A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06169319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*